Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW:FSE) announced in a news release it received approval from the South Korean government to launch a Phase 2 COVID-19 trial of the biopharma's repurposed drug, NP-120 (ifenprodil).
The study will evaluate this NMDA receptor antagonist in COVID-19-infected patients who have severe pneumonia. The 40 study patients will be randomized at a 1:1 ratio to receive either standard of care alone or standard of care plus ifenprodil. The trial will last four weeks.
The primary endpoint will be the rate of lung function improvement as measured by oxygen levels in the blood. Secondary endpoints will include rate of mechanical ventilation, effects on cough and breathlessness as reported by the patient, and mortality.
Trial enrollment is scheduled to start on May 8, 2020. The study's lead investigator will be Dr. Dong Sik Jung, an infectious disease professor at Dong-A University Hospital in Busan.
"This first human trial of Ifenprodil in COVID-19 patients is a major step forward with our new acute lung injury clinical research program," said Christopher J. Moreau, CEO of Algernon. "Positive Phase 2 data would be an important milestone as we continue to investigate Ifenprodil's therapeutic potential as a treatment for COVID-19, in addition to advancing our idiopathic pulmonary fibrosis and chronic cough program."
The company cautioned that "while it is preparing to begin a Phase 2 clinical trial shortly in South Korea, it is not making any express or implied claims that NP-120 (Ifenprodil) is an effective treatment for acute lung injury (ALI), the COVID-19 virus, or any other medical condition at this time." [NLINSERT]
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Algernon, a company mentioned in this article.